FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Rhea-AI Summary

FibroBiologics (NASDAQ: FBLG) has filed a patent application with the USPTO for methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. The biotechnology company, which holds 275+ patents, focuses on developing therapeutics using fibroblasts and fibroblast-derived materials.

The innovation enables the generation of stable multipotent cells directly from donor-derived fibroblasts, which can differentiate into various cell types including chondrocytes, osteocytes, hepatocytes, and cardiomyocytes. According to Chief Scientific Officer Hamid Khoja, this method allows for obtaining larger quantities of stable and scalable multipotent cells, with enhanced ability to form 3D spheroid structures.

Positive

• Patent filing strengthens intellectual property portfolio in regenerative medicine
• Technology enables larger quantities of stable and scalable multipotent cells
• Enhanced ability to form 3D spheroid structures expands therapeutic potential
• Method addresses long-standing challenges in scalable regenerative treatments

Negative

• Early-stage technology with no proven clinical success yet
• Significant R&D and clinical validation still required
• Company faces liquidity and capital resource challenges
• Unpredictable relationship between preclinical and clinical results

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications.

Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues.

“This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.”

Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics, said, “By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.”

For more information, please visit FibroBiologics’ website or email FibroBiologics at info@fibrobiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com. 

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

What is the significance of FBLG's new patent application for multipotent cells?

The patent covers methods for generating multipotent cells from donor tissue fibroblasts, enabling larger quantities of stable and scalable cells for clinical applications and expanding potential therapeutic uses.

How many patents does FibroBiologics (FBLG) currently have?

FibroBiologics has 275+ patents issued and pending, focusing on therapeutics development using fibroblasts and fibroblast-derived materials.

What cell types can FibroBiologics' multipotent fibroblasts differentiate into?

The multipotent fibroblasts can differentiate into multiple cell types including chondrocytes, osteocytes, hepatocytes, and cardiomyocytes.

What are the main advantages of FBLG's new multipotent cell generation method?

The method provides larger quantities of stable and easily scalable multipotent cells, enhanced ability to form 3D spheroid structures, and addresses challenges in scalable regenerative treatments.

What are the key risks facing FibroBiologics' (FBLG) technology development?

Key risks include liquidity challenges, unpredictable relationship between preclinical and clinical results, and the need for successful clinical validation of the technology.